Antiviral rift valley fever virus peptides and methods of use
AssigneeThe United States of America, as represented by the Secretary of the Army, on behalf of the United
InventorsCONNIE SCHMALJOHN, Robert F. Garry, Jeffrey W. Koehler, Mary Guttieri
Life of this patent
Estimating the term…
Abstract
The invention entails synthetic short peptides based on Rift Valley Fever Virus (RVFV) fusion protein. The peptides are broad-spectrum antivirals, and are useful for prophylactic treatment against or therapeutic treatment of infection by hemorrhagic fever viruses, such as RVFV, Ebola Virus, and Andes Virus, as well as vesicular stomatitis virus.
Claims20
Isolated antiviral Rift Valley Fever Virus (RVFV) peptide having the amino acid sequence selected from the group consisting of
- WNFFDWFSGLMSWFGGPLKLY (SEQ ID NO:5), designated RVFV-5,
- WNFFDWFSGLMSWFGGPLK (SEQ ID NO:6), designated RVFV-6,
- WNFFDWFSGLMSWFGGPLKTI (SEQ ID NO:7), designated RVFV-7,
- SWNFFDWFSGLMSWFGGPLK (SEQ ID NO:8), designated RVFV-8,
- SGSWNFFDWFSGLMSWFGG (SEQ ID NO:9), designated RVFV-9, and
- SGSWNFFDWFSGLMSWFGGPL (SEQ ID NO:10) designated RVFV-10.
A method of inhibiting the fusion of RVFV, vesicular stomatitis virus (VSV), and/or Ebola virus (EBOV) to a target cell, comprising the steps of
- a) exposing a peptide to a virion of RVFV, VSV and/or EBOV under conditions that the peptide binds to the virion,
- wherein the peptide is an antiviral RVFV peptide having the amino acid sequence selected from the group consisting of
- WNFFDWFSGLMSWFGGPLKLY (SEQ ID NO:5), designated RVFV-5,
- WNFFDWFSGLMSWFGGPLK (SEQ ID NO:6), designated RVFV-6,
- WNFFDWFSGLMSWFGGPLKTI (SEQ ID NO:7), designated RVFV-7,
- SWNFFDWFSGLMSWFGGPLK (SEQ ID NO:8), designated RVFV-8,
- SGSWNFFDWFSGLMSWFGG (SEQ ID NO:9), designated RVFV-9, and
- SGSWNFFDWFSGLMSWFGGPL (SEQ ID NO:10) designated RVFV-10
- and
- b) allowing the virion bound with the peptide to enter the target cell and bind to a viral fusion protein, so that the viral fusion protein does not fuse a viral membrane with a cellular membrane.
A method for preventing, treating or inhibiting post-exposure infection in a mammal by RVFV or VSV, and/or EBOV, comprising the step of:
- administering to a mammal that has been exposed or potentially will be exposed to RVFV, VSV and/or EBOV an antiviral composition comprising an RVFV peptide having the amino acid sequence selected from the group consisting of
- WNFFDWFSGLMSWFGGPLKLY (SEQ ID NO:5), designated RVFV-5,
- WNFFDWFSGLMSWFGGPLK (SEQ ID NO:6), designated RVFV-6,
- WNFFDWFSGLMSWFGGPLKTI (SEQ ID NO:7), designated RVFV-7,
- SWNFFDWFSGLMSWFGGPLK (SEQ ID NO:8), designated RVFV-8,
- SGSWNFFDWFSGLMSWFGG (SEQ ID NO:9), designated RVFV-9, and
- SGSWNFFDWFSGLMSWFGGPL (SEQ ID NO:10) designated RVFV-10,
- suspended in a biologically compatible medium.
An antiviral composition for treating, preventing or inhibiting infection in a mammal by RVFV or VSV, or EBOV, comprising an RVFV peptide having the amino acid sequence selected from the group consisting of
- WNFFDWFSGLMSWFGGPLKLY (SEQ ID NO:5), designated RVFV-5,
- WNFFDWFSGLMSWFGGPLK (SEQ ID NO:6), designated RVFV-6,
- WNFFDWFSGLMSWFGGPLKTI (SEQ ID NO:7), designated RVFV-7,
- SWNFFDWFSGLMSWFGGPLK (SEQ ID NO:8), designated RVFV-8,
- SGSWNFFDWFSGLMSWFGG (SEQ ID NO:9), designated RVFV-9, and
- SGSWNFFDWFSGLMSWFGGPL (SEQ ID NO:10) designated RVFV-10,
- suspended in a biologically compatible medium.
An antiviral composition for treating, preventing or inhibiting infection in a mammal by Andes Virus, comprising an RVFV peptide having the amino acid sequence of WNFFDWFSGLMSWFGGPLK (SEQ ID NO:6), designated RVFV-6,
- suspended in a biologically compatible medium.
A method of inhibiting the fusion of Andes virus (ANDV) to a target cell, comprising the steps of
- a) exposing a peptide to a virion of ANDV under conditions that the peptide binds to the virion,
- wherein the peptide is an antiviral RVFV peptide having the amino acid sequence of WNFFDWFSGLMSWFGGPLK (SEQ ID NO:6),
- b) allowing the virion bound with the peptide to enter the target cell and bind to a viral fusion protein so that the viral fusion protein does not fuse a viral membrane and a cellular membrane.
A method for preventing, treating or inhibiting post-exposure infection in a mammal by ANDV, comprising the step of:
- administering to a mammal that has been exposed or potentially has been exposed to ANDV an antiviral composition comprising a RVFV peptide having the amino acid sequence of WNFFDWFSGLMSWFGGPLK (SEQ ID NO:6),
- suspended in a biologically compatible medium.
A composition comprising an RVFV peptide having the amino acid sequence selected from the group consisting of
- WNFFDWFSGLMSWFGGPLKLY (SEQ ID NO:5), designated RVFV-5,
- WNFFDWFSGLMSWFGGPLK (SEQ ID NO:6), designated RVFV-6,
- WNFFDWFSGLMSWFGGPLKTI (SEQ ID NO:7), designated RVFV-7,
- SWNFFDWFSGLMSWFGGPLK (SEQ ID NO:8), designated RVFV-8,
- SGSWNFFDWFSGLMSWFGG (SEQ ID NO:9), designated RVFV-9, and
- SGSWNFFDWFSGLMSWFGGPL (SEQ ID NO:10) designated RVFV-10,
- tethered or conjugated to a drug or therapeutic, so as to form a peptide-drug or peptide-therapeutic composition.
Dependencies are inferred from the claim text.